Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Smart app aims to optimize heart failure meds

NCT ID NCT05858320

Disease control Sponsor: University of Michigan Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed Phase 3 trial tested a web application called SmartHF in 225 adults with heart failure and reduced ejection fraction. The app analyzes patient data and gives personalized medication recommendations that patients can share with their doctor. The goal was to see if using the app improves medication scores over 12 weeks compared to usual care.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
SmartHF web application (adaptive medication recommendations)
What this could lead to
If successful, this could provide a simple, patient-friendly tool to help doctors and patients optimize heart failure medications, potentially improving outcomes.
What could go wrong
This is a completed trial with 225 participants, so results are available but may not apply to all heart failure patients. The app only recommends medications; it does not prescribe them, so real-world impact depends on doctor uptake.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

225 people

The number who actually took part.

Started

Jul 2023

Finished

Dec 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age 18 years and older at screening 2. Diagnosis of heart failure with a left ventricular ejection fraction (LVEF) \</= 40% (HFrEF) 3. Have a general medicine provider or general cardiology provider for HFrEF 4. Have internet access and access to their health system's patient portal 5. Fluent in spoken and written English 6. At least two of the following: systolic blood pressure ≥ 110mmg, potassium ≤ 5.5, serum creatinine ≤ 2.5, heart rate ≥ 70 7. At least two eligible heart failure therapies (guideline-recommended BB, RASI, MRA, or SGLT2i) not yet initiated or below 50% of the target dose Exclusion Criteria: 1. End-stage HF (hospice candidate) 2. Actively treated cancer, except non-melanoma skin cancer 3. Implanted ventricular assist device 4. Current treatment with chronic inotropic therapy 5. Patient's provider for HFrEF care is considered an advanced HF specialist 6. Currently pregnant or intends to become pregnant during the study period 7. Dialysis

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Heart failure are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

heart failure systolic heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Heart failure

Contacts and locations

Locations

  • Emory University, Grady Hospital

    Atlanta, Georgia, 30303, United States

  • Henry Ford Hospital and Health System

    Detroit, Michigan, 48202, United States

  • Trinity Healthcare St. Joseph Mercy Ann Arbor

    Ypsilanti, Michigan, 48197, United States

  • University of Michigan

    Ann Arbor, Michigan, 48109, United States

  • Washington University, Barns Jewish Hospital

    St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.